EURONEXT-PAR$ABVX
Abivax SA · Q1 2025 earnings
Q1 2025 earnings · · Before market open · Investor relations
Briefing
Abivax reported increased R&D spending and a wider net loss in Q1 2025 compared to Q1 2024.
Abivax continued advancing clinical trials for obefazimod, with increased R&D expenses contributing to a higher net loss for the quarter. Despite lower revenue and financial losses, the company maintained a cash position to fund operations through Q4 2025.
- Net loss increased to €52.4M due to higher R&D expenses.
- Revenue declined to €994K, down from €1.19M a year earlier.
- Cash and equivalents stood at €103.6M at quarter-end.
- Company expects to fund operations through Q4 2025 with current resources.
Headline financials
Revenue & EPS history
Abivax SA · Revenue · Quarterly
$1.08M
Forward guidance
Abivax expects to continue advancing clinical trials for obefazimod with cash runway through Q4 2025 and plans for additional financing.
Tailwinds
- Phase 3 trials for obefazimod in UC fully enrolled as of April 2025.
- Cash reserves of €103.6M projected to fund operations through Q4 2025.
- First data readout for ABTECT Phase 3 trials expected in Q3 2025.
- Preclinical results support future combination therapies.
- ATM program allows potential access to $150M additional equity capital.
Headwinds
- Net loss widened by €9.5M year-over-year.
- R&D expenses increased due to clinical trial expansion.
- Financial result turned negative due to interest and FX losses.
- Revenue decreased 16% year-over-year.
- Uncertainty remains around future funding beyond Q4 2025.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 3 quarterly earnings reports · overlaid with Q1 2025
+0.7%
Avg return
Earnings day
+1.8%
Avg return
5 days after
+16.9%
Avg return
30 days after
67%
2 / 3 earnings
Positive
+1.5%
Q2 2025
Best reaction
-0.2%
Q1 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2025 | +1.5% | -6.7% | +0.7% | |
| Q1 2025 | -0.2% | +11.6% | +30.1% | |
| Q4 2023 | +0.9% | +0.4% | +20.1% | |
| Q2 2023 | — | — | — | |
| Q4 2022 | — | — | — | |
| Q2 2022 | — | — | — | |
| Q4 2021 | — | — | — | |
| Q2 2021 | — | — | — | |
| Q4 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q2 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro